Jim Simons Cue Biopharma, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.77 - $3.09 $330,694 - $577,313	186,833 Added 214.26%	274,033 $518,000
Q4 2023 Feb 13, 2024	BUY	$1.72 - $3.1 $47,128 - $84,940	27,400 Added 45.82%	87,200 $230,000
Q3 2023 Nov 14, 2023	SELL	$2.23 - $4.69 $212,296 - $446,488	-95,200 Reduced 61.42%	59,800 $138,000
Q2 2023 Aug 11, 2023	BUY	$3.11 - $4.91 $323,129 - $510,149	103,900 Added 203.33%	155,000 $566,000
Q1 2023 May 12, 2023	SELL	$2.41 - $3.74 $218,346 - $338,844	-90,600 Reduced 63.94%	51,100 $182,000
Q4 2022 Feb 13, 2023	SELL	$2.39 - $3.95 $679,828 - $1.12 Million	-284,447 Reduced 66.75%	141,700 $404,000
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $342,423 - $517,473	-153,553 Reduced 26.49%	426,147 $950,000
Q2 2022 Aug 12, 2022	BUY	$2.49 - $5.92 $150,396 - $357,568	60,400 Added 11.63%	579,700 $1.44 Million
Q1 2022 May 13, 2022	BUY	$4.41 - $12.28 $1.83 Million - $5.09 Million	414,700 Added 396.46%	519,300 $2.53 Million
Q4 2021 Feb 11, 2022	BUY	$10.86 - $17.85 $1.14 Million - $1.87 Million	104,600 New	104,600 $1.18 Million
Q1 2021 May 13, 2021	SELL	$11.2 - $16.09 $764,960 - $1.1 Million	-68,300 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$11.12 - $16.4 $613,779 - $905,214	-55,196 Reduced 44.69%	68,300 $854,000
Q3 2020 Nov 13, 2020	BUY	$15.05 - $23.54 $338,564 - $529,555	22,496 Added 22.27%	123,496 $1.86 Million
Q2 2020 Aug 13, 2020	BUY	$12.7 - $30.73 $261,708 - $633,253	20,607 Added 25.63%	101,000 $2.48 Million
Q1 2020 May 14, 2020	BUY	$9.85 - $22.27 $364,450 - $823,990	37,000 Added 85.27%	80,393 $1.14 Million
Q4 2019 Feb 13, 2020	BUY	$7.06 - $17.47 $306,354 - $758,075	43,393 New	43,393 $689,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account